title: Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
abstract: OBJECTIVE
  To compare the efficacy of therapy with a combination of disease-modifying antirheumatic drugs (DMARDs) versus therapy with a single DMARD in the prevention of work disability in patients with early rheumatoid arthritis (RA).
  
  
  METHODS
  In the Finnish Rheumatoid Arthritis Combination Therapy trial, 195 patients with recent-onset RA were randomly assigned to receive either combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone or single therapy with a DMARD with or without prednisolone. After 2 years, the drug treatment strategy was no longer restricted. At baseline, 162 patients (80 in the combination-treatment group and 82 in the single-treatment group) were still working or at least available for work. After 5 years of followup, data on all sick leave and retirement were obtained from social insurance registers or case records. The main outcome for each patient was the cumulative duration of all sick leaves and RA-related disability pensions, divided by the observation period during which the patient was not retired because of another disease or because of age.
  
  
  RESULTS
  The cumulative duration of work disability per patient-observation year was significantly lower in those randomized to combination therapy than in those randomized to single therapy: median 12.4 days (interquartile range [IQR] 0-54) versus 32.2 days (IQR 6-293) (P = 0.008, sex- and age-adjusted P = 0.009). This was mainly due to the difference in sick leaves (i.e., work disability periods </=300 days): median 11.7 days (IQR 0-44) per patient-observation year in those treated with combination therapy and 30.0 days (IQR 6-68) in those treated with single therapy (P = 0.002). No statistically significant difference was seen in RA-related disability pensions.
  
  
  CONCLUSIONS
  Aggressive initial treatment of RA with a combination of DMARDs improves 5-year outcome in terms of lost productivity in patients with RA of recent onset.
authors.affiliation: Lappeenranta Central Hospital, Lappeenranta, Finland. kari.puolakka@ekshp.fi
authors.forename: Kari
authors.initials: K
authors.lastname: Puolakka
authors.forename: Hannu
authors.initials: H
authors.lastname: Kautiainen
authors.forename: Timo
authors.initials: T
authors.lastname: Möttönen
authors.forename: Pekka
authors.initials: P
authors.lastname: Hannonen
authors.forename: Markku
authors.initials: M
authors.lastname: Korpela
authors.forename: Heikki
authors.initials: H
authors.lastname: Julkunen
authors.forename: Reijo
authors.initials: R
authors.lastname: Luukkainen
authors.forename: Kaisa
authors.initials: K
authors.lastname: Vuori
authors.forename: Leena
authors.initials: L
authors.lastname: Paimela
authors.forename: Harri
authors.initials: H
authors.lastname: Blåfield
authors.forename: Markku
authors.initials: M
authors.lastname: Hakala
authors.forename: Marjatta
authors.initials: M
authors.lastname: Leirisalo-Repo
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D004185:Disability Evaluation; D004359:Drug Therapy, Combination; D042241:Early Diagnosis; D004651:Employment; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage*; D007342:Insurance Benefits; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D010415:Pensions; D011239:Prednisolone / Q000008:administration & dosage; D012460:Sulfasalazine / Q000008:administration & dosage*
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D011239:Prednisolone; D008727:Methotrexate